Biomea Fusion Highlights Recent Updates and Anticipated 2024 …
WEBJan 9, 2024 · Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the ...
Investors & Media | Biomea Fusion
WEBBiomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and genetically defined cancers.
Biomea Fusion Reports Second Quarter 2024 Financial Results and ...
WEBContinued the development of the Biomea FUSION™ Platform technology. SECOND QUARTER 2024 FINANCIAL RESULTS. Cash, Cash Equivalents, and Restricted Cash: As of June 30, 2024, the Company had cash, cash equivalents and restricted cash of $113.7 million, compared to $177.2 million as of December 31, 2023.
Events - Biomea Fusion
WEBMar 9, 2024 · Virtual Fireside Chat with Oppenheimer & Co.: Type 2 Diabetes and New Treatment Options with Biomea Fusion (BMEA) Mgmt. & Key Opinion Leaders. Mar 2, 2023 at 12:00 PM EST.
Biomea Fusion Announces Appointment of Steve Morris, M.D. as …
WEBFeb 1, 2022 · Dr. Morris will lead clinical development of BMF-219, an irreversible covalent menin inhibitor currently in a Phase I clinical trial, and additional planned clinical programs. Company plans to initiate clinical development of BMF-219 in up to seven distinct tumor types, as well as diabetes, in 2022.
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical …
WEBREDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical.
Biomea Fusion Highlights Initial Data from the First Two Type 1 ...
WEBBiomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219. BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes.
Biomea Fusion Announces Positive Data from Initial Cohorts of …
WEBMar 28, 2023 · Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
WEBBMF-219 resulted in increased CCNA2 and PbK expression, similar to literature results from menin knockdown experiments. CCNA2 and PbK expression have been shown to support proliferation of beta cells, resulting in an increase in …
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq …
WEBREDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with metabolic diseases and genetically defined.